6533b855fe1ef96bd12afece
RESEARCH PRODUCT
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
Paolo RagoneseSimona MalucchiAntonio GalloMariangela D'onghiaViviana NocitiMarta RadaelliValentina TomassiniM. RodegherGiovanni Frisullo 2Vincenzina Lo ReDamiano PaolicelliPietro AnnovazziClaudio SolaroMassimiliano Calabrese 1Claudio GasperiniCarla Tortorellasubject
MaleTime FactorsThyroid GlandAutoimmunityAdverse effectmedicine.disease_causemultiple sclerosisGastroenterologythyroidAutoimmunityImmunosuppressive AgentRisk FactorsRetrospective StudiePrevalenceinterferon betaThyroidadverse effects; autoimmunity; glatiramer acetate; interferon beta; thyroid; multiple sclerosisMiddle AgedTreatment Outcomemedicine.anatomical_structureItalyNeurologymultiple sclerosiThyroid autoimmunityCohortFemaleSettore MED/26 - NeurologiaThyroid functionImmunosuppressive AgentsInterferon beta-1aHumanInterferon beta-1bmedicine.drugAdultmedicine.medical_specialtyTime FactorThyroid DiseaseRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansGlatiramer acetateAdverse effectRetrospective Studiesbusiness.industryRisk FactorMultiple sclerosisGlatiramer Acetatemedicine.diseaseThyroid DiseasesImmunologyadverse effectsNeurology (clinical)businessdescription
Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment. © The Author(s) 2014.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-01-01 |